400744-57-2 Usage
General Description
5-(3-Methylphenyl)-2-furoic acid is a chemical compound with the molecular formula C12H10O3. It belongs to the class of furoic acids, which are organic compounds containing a furan ring and a carboxylic acid group. This specific compound is characterized by the presence of a 3-methylphenyl group attached to the furoic acid structure. It is used in organic synthesis and pharmaceutical research, and its potential applications include being a precursor in the synthesis of various bioactive molecules. Additionally, it may also have industrial applications in the production of specialty chemicals or organic intermediates.
Check Digit Verification of cas no
The CAS Registry Mumber 400744-57-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,0,7,4 and 4 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 400744-57:
(8*4)+(7*0)+(6*0)+(5*7)+(4*4)+(3*4)+(2*5)+(1*7)=112
112 % 10 = 2
So 400744-57-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H10O3/c1-8-3-2-4-9(7-8)10-5-6-11(15-10)12(13)14/h2-7H,1H3,(H,13,14)
400744-57-2Relevant articles and documents
Shedding X-ray Light on the Role of Magnesium in the Activity of Mycobacterium tuberculosis Salicylate Synthase (MbtI) for Drug Design
Mori, Matteo,Stelitano, Giovanni,Gelain, Arianna,Pini, Elena,Chiarelli, Laurent R.,Sammartino, José C.,Poli, Giulio,Tuccinardi, Tiziano,Beretta, Giangiacomo,Porta, Alessio,Bellinzoni, Marco,Villa, Stefania,Meneghetti, Fiorella
, p. 7066 - 7080 (2020/07/28)
The Mg2+-dependent Mycobacterium tuberculosis salicylate synthase (MbtI) is a key enzyme involved in the biosynthesis of siderophores. Because iron is essential for the survival and pathogenicity of the microorganism, this protein constitutes an attractiv
PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS
-
, (2012/01/14)
Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of a metab
